MWMing-Wei Wang

Ming-Wei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ming-Wei Wang has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Jin-Peng Sun

    Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China; Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China

    2 shared publications
  • Xiao Yu

    Key Laboratory Experimental Teratology of the Ministry of Education and Department of Physiology, School of Basic Medical Sciences, Shandong University, Jinan, China

    2 shared publications
  • Zhao Yang

    Shandong University

    2 shared publications
  • Baoxue Yang

    Department of Pharmacology, School of Basic Medical Sciences Peking University Beijing China

    1 shared publication
  • Bo-Yang Cai

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China

    1 shared publication
  • Chang-Xiu Qu

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China

    1 shared publication

Latest Publications

  • DGKE acts as a negative regulator of podocyte migration and injury in glomerular diseases

    by Fuwen Zuo, Mingwei Wang, Junyao Du, Xiaofeng Wang, Pengzhong Ding, Qingsheng Han, Xiaorui Liu, Wei Tang, Yu Sun, Yan Zhang, et al.

  • Open Access

    Single hormone or synthetic agonist induces Gs/Gicoupling selectivity of EP receptors via distinct binding modes and propagating paths

    by Shen-Ming Huang, Meng-Yao Xiong, Lei Liu, Jianqiang Mu, Ming-Wei Wang, Ying-Li Jia, Kui Cai, Lu Tie, Chao Zhang, Sheng Cao, et al.

    To accomplish concerted physiological reactions, nature has diversified functions of a single hormone at at least two primary levels: 1) Different receptors recognize the same hormone, and 2) different cellular effectors couple to the same hormone–receptor pair [R.P. Xiao,Sci STKE2001, re15 (2001); L. Hein, J. D. Altman, B.K. Kobilka,Nature402, 181–184 (1999); Y. Daaka, L. M. Luttrell, R. J. Lefkowitz,Nature390, 88–91 (1997)]. Not only these questions lie in the heart of hormone actions and receptor signaling but also dissecting mechanisms underlying these questions could offer therapeutic routes for refractory diseases, such as kidney injury (KI) or X-linked nephrogenic diabetes insipidus (NDI). Here, we identified that Gs-biased signaling, but not Giactivation downstream of EP4, showed beneficial effects for both KI and NDI treatments. Notably, by solving Cryo-electron microscope (cryo-EM) structures of EP3-Gi, EP4-Gs, and EP4-Giin complex with endogenous prostaglandin E2(PGE2)or two synthetic agonists and comparing with PGE2-EP2-Gsstructures, we found that unique primary sequences of prostaglandin E2 receptor (EP) receptors and distinct conformational states of the EP4 ligand pocket govern the Gs/Gitransducer coupling selectivity through different structural propagation paths, especially via TM6 and TM7, to generate selective cytoplasmic structural features. In particular, the orientation of the PGE2ω-chain and two distinct pockets encompassing agonist L902688 of EP4 were differentiated by their Gs/Gicoupling ability. Further, we identified common and distinct features of cytoplasmic side of EP receptors for Gs/Gicoupling and provide a structural basis for selective and biased agonist design of EP4 with therapeutic potential.


  • Activation of PTH1R alleviates epididymitis and orchitis through Gq and β-arrestin-1 pathways

    by Ming-Wei Wang, Zhao Yang, Xu Chen, Shu-Hua Zhou, Ge-Lin Huang, Jian-Ning Sun, Hui Jiang, Wen-Ming Xu, Hao-Cheng Lin, Xiao Yu, et al.

    Inflammation in the epididymis and testis contributes significantly to male infertility. Alternative therapeutic avenues treating epididymitis and orchitis are expected since current therapies using antibiotics have limitations associated to side effects and are commonly ineffective for inflammation due to nonbacterial causes. Here, we demonstrated that type 1 parathyroid hormone receptor (PTH1R) and its endogenous agonists, parathyroid hormone (PTH) and PTH-related protein (PTHrP), were mainly expressed in the Leydig cells of testis as well as epididymal epithelial cells. Screening the secretin family G protein–coupled receptor identified that PTH1R in the epididymis and testis was down-regulated in mumps virus (MuV)- or lipopolysaccharide (LPS)-induced inflammation. Remarkably, activation of PTH1R by abaloparatide (ABL), a Food and Drug Administration–approved treatment for postmenopausal osteoporosis, alleviated MuV- or LPS-induced inflammatory responses in both testis and epididymis and significantly improved sperm functions in both mouse model and human samples. The anti-inflammatory effects of ABL were shown to be regulated mainly through the Gq and β-arrestin-1 pathway downstream of PTH1R as supported by the application of ABL in Gnaq± and Arrb1−/− mouse models. Taken together, our results identified an important immunoregulatory role for PTH1R signaling in the epididymis and testis. Targeting to PTH1R might have a therapeutic effect for the treatment of epididymitis and orchitis or other inflammatory disease in the male reproductive system. Significance Currently, male infertility has become a public health issue. The inflammations in the epididymis and testis are estimated to account for 6 to 15% of male infertility and thus have attracted increasing attention. Conventional therapies for epididymitis and orchitis using antibiotics have limitations in terms of side effects and ineffectiveness for nonbacterial inflammations, thus highlighting an urgent need for novel therapeutic strategies. Here, the screening of secretin family G protein–coupled receptors (GPCRs) enabled us to identify that activation of PTH1R by a Food and Drug Administration–approved osteoporosis drug abaloparatide effectively counteracts epididymitis and orchitis through selective transducer-mediated pathways. Our results offer potential therapeutics to treat epididymitis and orchitis by targeting GPCRs other than traditional antibiotic therapies.